SummaryJoin Avalere for a live discussion on key trends in drug pricing, value, and regulatory shifts, and how these trends will impact manufacturers.
Following our annual Healthcare Industry Outlook webinar, we surveyed 1,400 healthcare stakeholders and found that life sciences companies are prioritizing 3 key initiatives moving into 2022:
- Value-based approaches to care, including quality and performance management
- Defining and demonstrating value of drugs
- Legislative and regulatory efforts related to drug pricing
In our spring 2022 Life Sciences Perspective, Avalere experts took a deeper look into these topics and how they may impact your business as we move into Q2.
Panel 1: Value-based approaches to care including quality & performance management
Panel 2: Approaches to defining & demonstrating value of drugs
Panel 3: Legislative & regulatory efforts related to drug pricing
produces measurable results. Let's work together.